- Home
- AUTL vs DNTH Comparison
AUTL vs DNTH Comparison
Compare AUTL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- DNTH
- Stock Information
- Founded
- AUTL 2014
- DNTH 2015
- Country
- AUTL United Kingdom
- DNTH United States
- Employees
- AUTL N/A
- DNTH N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- DNTH Health Care
- Exchange
- AUTL Nasdaq
- DNTH Nasdaq
- Market Cap
- AUTL 625.4M
- DNTH 568.6M
- IPO Year
- AUTL 2018
- DNTH N/A
- Fundamental
- Price
- AUTL $2.31
- DNTH $18.05
- Analyst Decision
- AUTL Strong Buy
- DNTH Strong Buy
- Analyst Count
- AUTL 5
- DNTH 8
- Target Price
- AUTL $9.32
- DNTH $53.00
- AVG Volume (30 Days)
- AUTL 2.4M
- DNTH 262.4K
- Earning Date
- AUTL 08-07-2025
- DNTH 08-07-2025
- Dividend Yield
- AUTL N/A
- DNTH N/A
- EPS Growth
- AUTL N/A
- DNTH N/A
- EPS
- AUTL N/A
- DNTH N/A
- Revenue
- AUTL $9,011,000.00
- DNTH $6,524,000.00
- Revenue This Year
- AUTL $461.76
- DNTH N/A
- Revenue Next Year
- AUTL $112.66
- DNTH N/A
- P/E Ratio
- AUTL N/A
- DNTH N/A
- Revenue Growth
- AUTL N/A
- DNTH 102.36
- 52 Week Low
- AUTL $1.11
- DNTH $13.37
- 52 Week High
- AUTL $5.00
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- AUTL 69.32
- DNTH 50.80
- Support Level
- AUTL $1.98
- DNTH $17.11
- Resistance Level
- AUTL $2.10
- DNTH $18.48
- Average True Range (ATR)
- AUTL 0.13
- DNTH 1.10
- MACD
- AUTL -0.00
- DNTH 0.08
- Stochastic Oscillator
- AUTL 73.63
- DNTH 59.86
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.